Asian Journal of Oncology最新文献_第2页

Action of ultra-diluted ethanol extract of Bryonia alba on HepG2 liver cancer cells 超稀释乙醇提取物对HepG2肝癌细胞的作用

Asian Journal of Oncology Pub Date : 2023-09-26 DOI: 10.25259/asjo-2022-28-(372)

Sanket Bandyopadhyay, Debasmita Chatterjee, Banhishikha Singh, Krishnendu Paira, Satadal Das

引用次数: 0

Pathophysiology and management of hypercalcemia in malignancy 恶性肿瘤高钙血症的病理生理学和治疗

Asian Journal of Oncology Pub Date : 2023-09-16 DOI: 10.25259/asjo-2022-27-(371)

Bella Yunita, Rahmat Cahyanur

引用次数: 0

Clinical profiles and survival outcomes of adult patients with multiple myeloma at a tertiary hospital in the Philippines 菲律宾一家三级医院成年多发性骨髓瘤患者的临床概况和生存结果

Asian Journal of Oncology Pub Date : 2023-09-09 DOI: 10.25259/asjo-2021-66-(298)

Jeremiah R. Vallente, Carlo Francisco N. Cortez, Ma. Angelina L. Mirasol

{"title":"Clinical profiles and survival outcomes of adult patients with multiple myeloma at a tertiary hospital in the Philippines","authors":"Jeremiah R. Vallente, Carlo Francisco N. Cortez, Ma. Angelina L. Mirasol","doi":"10.25259/asjo-2021-66-(298)","DOIUrl":"https://doi.org/10.25259/asjo-2021-66-(298)","url":null,"abstract":"Objectives The Filipino population is largely underrepresented in the currently available literature on multiple myeloma (MM). Herein, we aimed to determine the clinical profile, treatment, and outcomes of adult Filipinos with MM. Material and Methods The records of 74 patients with MM seen at our institution from 2016 to 2019 were retrospectively reviewed. Results The median age at diagnosis was 54 years, with the majority lumped in the 40–65 years age group. At diagnosis, anemia (hemoglobin <100 g/L) was present in 36 (64.3%) patients, but hypercalcemia (calcium ≥2.75 mmol/L) and azotemia (creatinine ≥177 umol/L) were seen in only 9 (20.0%) and 18 (34.0%) patients, respectively. Novel drugs (bortezomib, thalidomide, and lenalidomide) were used in 54 (84.4%) patients for frontline treatment. The overall response rate was 70.0% and the median overall survival (OS) was 60 months. On univariate analysis, only hemoglobin and the serum albumin levels affected survival. Conclusion Aside from the trend of a younger age at diagnosis, there are no unique clinical characteristics of MM seen in Filipinos. The longer OS may reflect the availability of newer drugs in the recent decade, but larger studies are needed to investigate the prognostic significance of several clinical and treatment parameters.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136194035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Serum microRNA-210 as a predictor of neoadjuvant chemotherapy resistance in breast cancer 血清微小RNA-210预测癌症新辅助化疗耐药性

Asian Journal of Oncology Pub Date : 2023-08-03 DOI: 10.25259/asjo-2022-36-(391)

Doaa Naeem, Hanan Kamal Abdelaziz, Nadia Ahmed Barghash, M. Soliman, Hazem Farag Mannaa

{"title":"Serum microRNA-210 as a predictor of neoadjuvant chemotherapy resistance in breast cancer","authors":"Doaa Naeem, Hanan Kamal Abdelaziz, Nadia Ahmed Barghash, M. Soliman, Hazem Farag Mannaa","doi":"10.25259/asjo-2022-36-(391)","DOIUrl":"https://doi.org/10.25259/asjo-2022-36-(391)","url":null,"abstract":"\u0000\u0000Breast cancer (BC) is a major global health issue as it is the most common malignancy in women. Despite, the role of neoadjuvant chemotherapy (NAC) in early BC has been established, there is a non-small proportion of patients who might develop chemoresistance. Several studies have investigated the relationship between microRNA-210 (miRNA-210) and neoadjuvant chemoresistance in BC with controversial results. Thus, this study aimed to evaluate the role of miRNA-210 as a predictor for chemoresistance in BC receiving NAC.\u0000\u0000\u0000\u0000The study enrolled 15 chemo-sensitive and 15 chemo-resistant patients with BC receiving NAC. In addition, 10 newly-diagnosed BC patients before treatment and 10 healthy women were recruited as controls. Serum samples from all patients and controls were withdrawn and measurements of miRNA-210 levels using quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR) were done and compared.\u0000\u0000\u0000\u0000The median value of miRNA-210 level was 1.53, 0.27, 0.52, and 1.35 in chemo-sensitive, chemo-resistant, newly-diagnosed, and control groups, respectively. A statistically significant difference (Chi square = 9.801, p = 0.020, df = 3) was found in the mean serum miRNA-210 among the four different groups. Using logistic regression model, low serum miRNA-210 expression level was found to be a predictive factor of chemo-resistance with p = 0.038 (OR of 0.103, 95% CI = 0.012 –0.886). Using the receiver operating characteristic curve, it was found that the area under the curve (AUC) was 0.747 (95% CI = 0.550 –0.943). \u0000\u0000\u0000\u0000Serum miRNA-210 could be an effective predictive biomarker for chemoresistance in BC patients receiving NAC.\u0000","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47982875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessment of level IIB lymph nodes in oral cancer - Should we spare or care? 口腔癌患者IIB级淋巴结的评估——我们应该保留还是护理?

Asian Journal of Oncology Pub Date : 2023-07-18 DOI: 10.25259/asjo-2022-40-(395)

S. Shanmugam, S. Susikar, Arun Victor Jebasingh

{"title":"Assessment of level IIB lymph nodes in oral cancer - Should we spare or care?","authors":"S. Shanmugam, S. Susikar, Arun Victor Jebasingh","doi":"10.25259/asjo-2022-40-(395)","DOIUrl":"https://doi.org/10.25259/asjo-2022-40-(395)","url":null,"abstract":"The extent of neck dissection over the years has evolved from a radical neck dissection to a super-selective neck dissection with an attempt to achieve a balance between oncological safety and acceptable morbidity. There is an ongoing debate concerning dissection of level IIB in both node negative and positive patients, primarily due to the low incidence of metastasis in this region and possible spinal accessory nerve injury. In this study, we intended to find the rate of metastasis to level IIB nodes in patients who were treated with neck dissection for oral cancers.\u0000\u0000\u0000\u0000Patients with squamous cell carcinoma of the oral cavity who underwent neck dissection were analyzed. Patients with clinically node negative (cN0) disease underwent selective neck dissection (SND), whereas patients with clinically node positive (cN+) disease underwent modified radical neck dissection (MRND).\u0000\u0000\u0000\u0000Out of the total 34 patients, 12 patients underwent MRND and 22 patients underwent SND. In the MRND group, three patients (25%) had positive level IIB nodes. The median number of IIB nodes removed was two and the median number of positive IIB nodes was one. In the SND group, the median number of IIB nodes removed was three and none of the patients had positive level IIB node.\u0000\u0000\u0000\u0000In oral cancer with cN+, routine dissection of level IIB nodes has both therapeutic and prognostic values. Whereas, in patients with cN0, routine dissection of level IIB nodes can be omitted. Further large volume studies are needed on cN0 disease.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41696325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metaplastic squamous cell carcinoma of the breast – A rare case report 乳腺中变鳞状细胞癌——一例罕见病例报告

Asian Journal of Oncology Pub Date : 2023-07-18 DOI: 10.25259/asjo-2022-32-(382)

Mohsina Hussain, A. Adhav, Sirshendu Roy, Yasam Venkata Ramesh, R. Nagarkar

引用次数: 0

Novel method of identifying spinal accessory nerve during modified radical neck dissection in level 2: “SMS Hospital point” and “Upward Pointing Arrow” sign 改良2级颈清扫术中脊髓副神经识别的新方法：“SMS医院点”和“向上箭头”标志

Asian Journal of Oncology Pub Date : 2023-07-17 DOI: 10.25259/asjo-2022-52-(413)

Bhushan Sanjay Bhalgat

引用次数: 0

Rare lung cancer subtype discovery by bone metastases: Synchronous traits 通过骨转移发现罕见的癌症亚型：同步特征

Asian Journal of Oncology Pub Date : 2023-07-17 DOI: 10.25259/asjo-2022-49-(407)

Souhail El Alami, A. Laraichi, M. Abakka, Naoufal El Ghoul, Soukaina El Aouni, A. Bennis, O. Zaddoug, A. Zine, M. Benchakroun, M. Tanane, S. Bouabid

{"title":"Rare lung cancer subtype discovery by bone metastases: Synchronous traits","authors":"Souhail El Alami, A. Laraichi, M. Abakka, Naoufal El Ghoul, Soukaina El Aouni, A. Bennis, O. Zaddoug, A. Zine, M. Benchakroun, M. Tanane, S. Bouabid","doi":"10.25259/asjo-2022-49-(407)","DOIUrl":"https://doi.org/10.25259/asjo-2022-49-(407)","url":null,"abstract":"\u0000\u0000This study investigates the synchronous traits of a rare lung cancer subtype, specifically Large Cell Neuroendocrine Carcinoma (LCNEC), discovered through bone metastases. Bone metastases are a common occurrence in lung cancer, significantly impacting the quality of life and survival of patients. Synchronous bone metastasis (SBM), defined as bone metastases diagnosed within three months of lung cancer diagnosis, and metachronous bone metastasis (MBM), diagnosed more than three months after lung cancer diagnosis, exhibit distinct clinicopathological characteristics, therapeutic sensitivities, and prognostic outcomes. This article presents a visual case discussion of a 64-year-old male patient who experienced a pathological fracture of the proximal femur, leading to the incidental discovery of LCNEC through bone biopsy. Further imaging and diagnostic tests confirmed the presence of a primary lung tumor and bone metastases. The treatment approach for LCNEC remains challenging due to limited data and varying outcomes reported in the literature, however our patient received cisplatin with etoposide chemotherapy following fracture management. The findings emphasize the importance of recognizing rare lung cancer subtypes, such as LCNEC, through bone metastases and tailoring individualized treatment plans.\u0000","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47419444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Feasibility of hypofractionated pelvic radiotherapy with parametrial and nodal simultaneous integrated boost for locally advanced cervical cancers: dummy run for the HYACINCT trial 子宫旁和淋巴结同时综合增强低分割盆腔放疗治疗局部晚期宫颈癌的可行性：HYACINCT试验的模拟运行

Asian Journal of Oncology Pub Date : 2023-07-14 DOI: 10.25259/asjo_2_2023

W. Bacorro, Stellar Marie Cabrera, M. Bojador, M. Dumago, K. Baldivia, T. S. Sy Ortin

{"title":"Feasibility of hypofractionated pelvic radiotherapy with parametrial and nodal simultaneous integrated boost for locally advanced cervical cancers: dummy run for the HYACINCT trial","authors":"W. Bacorro, Stellar Marie Cabrera, M. Bojador, M. Dumago, K. Baldivia, T. S. Sy Ortin","doi":"10.25259/asjo_2_2023","DOIUrl":"https://doi.org/10.25259/asjo_2_2023","url":null,"abstract":"\u0000\u0000The HYACINCT trial will investigate the role of dose-adapted hypofractionated pelvic radiotherapy in patients with locally advanced cervical cancer who are ineligible for cisplatin. This dummy run evaluated the feasibility of the protocol treatment planning objectives using intensity-modulated radiotherapy (IMRT) and volumetric arc therapy (VMAT).\u0000\u0000\u0000\u0000The HYACINCT protocol defines a set of guidelines for image acquisition, target and organ delineation, and treatment planning objectives. Fifteen dummy cases were prepared, five each for three levels of dose requirements: 40 Gy without boost, and with boost to 45 Gy and to 48 Gy. IMRT and VMAT plans were prepared for each case, evaluated and assigned penalty and compliance scores according to planning objectives, and subjected to quality control. IMRT and VMAT plans were compared in terms of treatment plan quality (target coverage, penalty, and compliance scores), and treatment delivery. Tumor extent (T-stage, T-score), nodal status, and PTV volumes (in cc) were examined as potential determinants of penalty and compliance scores.\u0000\u0000\u0000\u0000IMRT was able to meet the planning objectives for all but one case; and VMAT, for all cases. All plans passed the quality control check. IMRT and VMAT were equivalent in terms of target coverage and penalty and compliance scores, but the latter was associated with better treatment delivery. T-score was a determinant for the penalty score.\u0000\u0000\u0000\u0000The HYACINCT radiotherapy protocol is feasible with either IMRT or VMAT. VMAT may be beneficial in more extensive cases, as measured by the T-score.\u0000\u0000\u0000\u0000NCT05210270\u0000","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49535045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiology and outcome of glioblastoma multiforme: A tertiary care experience 多形性胶质母细胞瘤的流行病学和预后:三级护理经验

Asian Journal of Oncology Pub Date : 2023-07-07 DOI: 10.25259/asjo-2022-65-(429)

T. Tali, Fiza Amin, ShahidRashid Sofi, M. Sofi, N. Dar

引用次数: 0